Skip to main content
AmigoFish

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

Back to Pharmaceutical Executive · Report a problem